Monopar Therapeutics (MNPR) insider trading.
In Q3 2026, insiders at Monopar Therapeutics reported 36 non-derivative transactions on 9 Forms 3, 4 and 5: 0 open-market purchases and 23 sales worth $4.2M.
- Transactions
- 36
- Purchases (P)
- 0
- Sales (S)
- 23
- Net shares, P minus S
- -43,521
- Insiders
- 6
- Last filed
- 2026-09-28
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Tsuchimoto Kim R | Director | 14 | 0 | 12 |
| Robinson Chandler | Director, Officer · Chief Executive Officer | 8 | 0 | 4 |
| Anderson Raymond | Director | 8 | 0 | 6 |
| Rioux Patrice | Other | 2 | 0 | 1 |
| Cittadine Andrew | Officer · Chief Operating Officer | 2 | 0 | 0 |
| Vu Quan Anh | Officer · Chief Financial Officer | 2 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-24 | Robinson Chandler | S (D) | 600 | $89.79 | 99,267 | Form 4 |
| 2026-09-24 | Robinson Chandler | S (D) | 8,368 | $88.97 | 99,867 | Form 4 |
| 2026-09-24 | Robinson Chandler | S (D) | 9,638 | $87.96 | 108,235 | Form 4 |
| 2026-09-24 | Robinson Chandler | S (D) | 10,450 | $87.15 | 117,873 | Form 4 |
| 2026-09-24 | Robinson Chandler | M (A) | 14,056 | $30 | 113,323 | Form 4 |
| 2026-09-24 | Robinson Chandler | M (A) | 15,000 | $14 | 128,323 | Form 4 |
| 2026-08-26 | Tsuchimoto Kim R | S (D) | 700 | $110.65 | 2,290 | Form 4/A |
| 2026-08-26 | Tsuchimoto Kim R | S (D) | 602 | $112.93 | 590 | Form 4/A |
| 2026-08-26 | Tsuchimoto Kim R | S (D) | 590 | $113.84 | 0 | Form 4/A |
| 2026-08-26 | Tsuchimoto Kim R | S (D) | 615 | $109.56 | 2,990 | Form 4/A |
| 2026-08-26 | Tsuchimoto Kim R | S (D) | 485 | $108.83 | 3,605 | Form 4/A |
| 2026-08-26 | Tsuchimoto Kim R | M (A) | 2,035 | $14 | 4,090 | Form 4/A |
| 2026-08-26 | Tsuchimoto Kim R | M (A) | 2,055 | $30 | 2,055 | Form 4/A |
| 2026-08-26 | Tsuchimoto Kim R | S (D) | 1,098 | $111.84 | 1,192 | Form 4/A |
| 2026-08-26 | Tsuchimoto Kim R | S (D) | 602 | $112.93 | 7,986 | Form 4 |
| 2026-08-26 | Tsuchimoto Kim R | S (D) | 1,098 | $111.84 | 8,588 | Form 4 |
| 2026-08-26 | Tsuchimoto Kim R | S (D) | 700 | $110.65 | 9,686 | Form 4 |
| 2026-08-26 | Tsuchimoto Kim R | S (D) | 615 | $109.56 | 10,386 | Form 4 |
| 2026-08-26 | Tsuchimoto Kim R | S (D) | 590 | $113.84 | 7,396 | Form 4 |
| 2026-08-26 | Tsuchimoto Kim R | S (D) | 485 | $108.83 | 11,001 | Form 4 |
| 2026-08-26 | Rioux Patrice | S (D) | 1 | $111.26 | 5,065 | Form 4 |
| 2026-08-26 | Rioux Patrice | M (A) | 1,380 | $0.01 | 5,066 | Form 4 |
| 2026-08-25 | Anderson Raymond | S (D) | 646 | $111.07 | 7,175 | Form 4/A |
| 2026-08-25 | Anderson Raymond | M (A) | 1,402 | $30 | 6,775 | Form 4/A |
| 2026-08-25 | Anderson Raymond | M (A) | 1,740 | $30 | 8,515 | Form 4/A |
| 2026-08-25 | Anderson Raymond | S (D) | 694 | $110.04 | 7,821 | Form 4/A |
| 2026-08-25 | Anderson Raymond | S (D) | 1,802 | $113.05 | 5,373 | Form 4/A |
| 2026-08-25 | Anderson Raymond | S (D) | 694 | $110.04 | 26,169 | Form 4 |
| 2026-08-25 | Anderson Raymond | S (D) | 646 | $110.07 | 25,523 | Form 4 |
| 2026-08-25 | Anderson Raymond | S (D) | 1,802 | $113.05 | 23,751 | Form 4 |
| 2026-06-30 | Cittadine Andrew | F (D) | 2,309 | $92.59 | 55,614 | Form 4 |
| 2026-06-30 | Cittadine Andrew | M (A) | 5,254 | — | 57,923 | Form 4 |
| 2026-06-30 | Robinson Chandler | M (A) | 12,873 | — | 103,351 | Form 4 |
| 2026-06-30 | Robinson Chandler | F (D) | 4,084 | $92.59 | 99,267 | Form 4 |
| 2026-06-30 | Vu Quan Anh | M (A) | 1,228 | — | 2,728 | Form 4 |
| 2026-06-30 | Vu Quan Anh | F (D) | 507 | $92.59 | 2,221 | Form 4 |
Transaction codes in this quarter
Get MNPR insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1645469&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · MNPR company page · Monopar Therapeutics on SEC.gov
Questions
Are insiders buying or selling Monopar Therapeutics (MNPR)?
In Q3 2026, insiders at Monopar Therapeutics reported 36 non-derivative transactions on 9 Forms 3, 4 and 5: 0 open-market purchases and 23 sales worth $4.2M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Monopar Therapeutics insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/mnpr.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.